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Abstract 
 
Introduction 
Treatment of type 2 diabetes with sodium-glucose cotransporter 2 (SGLT2) inhibitors 
may result in genital fungal infections. We investigated possible risk factors for 
developing such infections among patients treated with the SGLT2 inhibitor 
dapagliflozin. 
 
Methods 
The Association of British Clinical Diabetologists (ABCD) collected data on patients 
treated with dapagliflozin in routine clinical practice from 59 diabetes centres. We 
assessed possible associations of patient’s age, diabetes duration, body mass index, 
glycated haemoglobin, renal function, patient sex, ethnicity and prior genital fungal 
infection, urinary tract infection, urinary incontinence or nocturia, with the occurrence 
of ≥1 genital fungal infection within 26 weeks of treatment. 
 
Results 
1049 out of 1116 patients (476 women, 573 men) were analysed. Baseline 
characteristics were, mean±SD, age 56.7±10.2 years, BMI 35.5±6.9 kg/m2 and 
HbA1c 9.4±1.5%. Only patient sex (13.2% women vs 3.3% men) and prior history of 
genital fungal infection (21.6% vs 7.3%) were found to be associated with 
occurrence of genital fungal infections after dapagliflozin treatment, adjusted OR 
4.22 [95%CI 2.48,7.19], P < 0.001 and adjusted OR 2.41 [95% CI 1.04,5.57], P = 
0.039, respectively. 
 
Conclusion 
Women and patients with previous genital fungal infections had higher risks of 
developing genital fungal infections with dapagliflozin treatment.  
Introduction 
Type 2 diabetes is characterised by several pathophysiological disruptions including 
defects in insulin secretion by the pancreas, increased hepatic glucose output and 
increased insulin resistance in the muscle. It is also now recognised that an adaptive 
increase in glucose reabsorption in the kidney tubules, mediated by sodium-glucose 
cotransporters 1 and 2 (SGLT1 and SGLT2), limits glucosuria and contributes to 
glucose dysregulation in type 2 diabetes. SGLT2, being higher in capacity and lower 
in affinity than SGLT1, has become a viable target for pharmacotherapy [1]. 
Initially available SGLT2 inhibitors include dapagliflozin, canagliflozin and 
empagliflozin. Among other effects, treatment with SGLT2 inhibitors results in 
increased glucosuria and natriuresis, and leads to improvements in glycaemia, body 
weight and blood pressure among patients with type 2 diabetes [1,2]. A recent trial 
utilising empagliflozin has also demonstrated treatment-led reduction in 
hospitalisation for heart failure and cardiovascular deaths among patients with type 2 
diabetes with high cardiovascular risk [3]. SGLT2 inhibitors are recommended as an 
option for second or third line therapy in addition to metformin by a joint position 
statement by the American Diabetes Association and European Association for the 
Study of Diabetes [4]. 
Adverse events associated with SGLT2 inhibitor treatment include genital fungal 
infections, urinary tract infection, volume-related events (hypotension, syncope or 
dehydration), hypoglycaemia and rarely, ketoacidosis [5-7]. Of these, genital fungal 
infections appear to be the most prevalent and consistent finding among various 
trials involving SGLT2 inhibitors. Diabetes patients are at an increased risk of genital 
fungal infections compared with non-diabetes patients [8]. By inducing glucosuria, 
treatment with SGLT2 inhibitors likely increases this risk further [9]. Manifestations 
include vulvo-vaginal infections in female patients and balanitis or balanoposthitis in 
male patients. Typically, trials of SGLT2 inhibitors have shown genital fungal 
infections to be more common among women, occur early after treatment initiation 
(within 24 weeks), and are usually not severe enough to warrant treatment 
discontinuation [9,10].  
The Association of British Clinical Diabetologists (ABCD) is the diabetes specialist 
society in the UK. ABCD has been conducting nationwide audits of new diabetes 
therapies once they become available for use in routine clinical practice, including 
thus far audits on the glucagon-like peptide-1 receptor agonists exenatide twice 
daily, liraglutide and exenatide once weekly, as well as on dapagliflozin, canagliflozin 
and insulin degludec. These audits hoped to accelerate learning of the new therapies 
and extend surveillance of adverse events in a real-world setting. All the audits bear 
similar designs including nationwide solicitation but voluntary participation of 
diabetes centres, collection of data of patients on certain diabetes treatments based 
on routine treatment decisions and clinical justification of their use, and utilisation of 
purposed-built audit software to collect pre-specified audit queries. We utilised data 
from the current ABCD dapagliflozin audit in an attempt to identify clinical predictors 
for developing genital fungal infections among patients treated with dapagliflozin. 
 
Methods 
Subjects 
ABCD invited diabetes centres in hospitals and primary care across UK to submit de-
identified data of patients routinely treated with dapagliflozin 10mg daily. A few 
diabetes centres from Hong Kong, Brazil and Australia were also invited to 
participate as “proof of concept” that a larger scale international audit database can 
be achieved. Between October 2014 and September 2016, 59 diabetes centres 
enrolled and submitted varying degrees of data depending on date of participation, 
the frequency of patients’ health visits and duration of dapagliflozin treatment that 
had taken place.  
Data requested included patients’ age, sex, ethnicity as well as pre- and post-
dapagliflozin treatment information including diabetes treatments, glycated 
haemoglobin (HbA1c), body weight, body mass index (BMI), systolic and diastolic 
blood pressure, lipid parameters, alanine transaminotransferase and creatinine, 
whenever these data were available. We accepted laboratory results from individual 
participating centres. Contributors were asked to identify prior history of genital 
fungal infections and urinary tract infections within the previous one year, urinary 
incontinence, nocturia, as well as to report these events or any-other adverse events 
after treatment. 
The audit received data on 1116 patients with at least one follow-up visit after 
dapagliflozin was initiated. Sixty-four patients with less than 12 weeks data 
contribution or follow-up, this not being due to discontinuation of dapagliflozin within 
12 weeks of initiation, were excluded. Three patients were excluded due to previous 
SGLT2 inhibitor use. Data on the remaining 1049 patients were analysed. 
 
Outcome and risk variables 
Patients were divided into those who developed ≥1 genital fungal infection within 26 
weeks of treatment and those who did not. We included genital fungal infection 
proven by microbiology or clinical examination or when there were suggestive 
symptoms such as pruritus or redness in the genital area. We then assessed 
possible associations of patient’s age, duration of diabetes, BMI, HbA1c, estimated 
glomerular filtration rate (eGFR), sex, ethnicity, previous genital fungal infection, 
previous urinary tract infection, previous urinary incontinence and previous nocturia 
with the development of genital fungal infections. eGFR was calculated using the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 
 
Statistical analyses 
Univariate associations were tested using Student’s t-test and Chi-Square analysis 
for continuous and categorical variables, respectively. Fisher’s exact test was used 
for categorical variables when the number of events was less than five. Variables 
with statistically significant association in univariate analyses (P < 0.05) were entered 
into a binary logistic regression analysis. Analyses were performed combining 
female and male patients together and then separately to exclude sex-specific 
interactions. Statistical analyses were performed using Minitab® Release 14 (Minitab 
Ltd, Coventry, UK). 
 
Results 
The overall proportion of patients reporting ≥1 treatment emergent genital fungal 
infections was 82/1049 (7.8%). The majority (95.1%) of the reports of genital fungal 
infection occurred in the first follow-up visit, which occurred at a median of 18 
[interquartile range 13-26] weeks after starting dapagliflozin. 109 (10.4%) patients 
discontinued dapagliflozin permanently within 26 weeks, 25 (2.4%) due to issues 
with genital fungal infections. 
Baseline characteristics of patients (476 women and 573 men) and possible 
association with subsequent genital fungal infections are shown in Table 1 and 2. 
Genital fungal infections were more common among women (13.2%) compared with 
men (3.3%) (difference P < 0.001). Patients reporting a history of genital fungal 
infections were also more likely to have infection after dapagliflozin treatment 
compared with patients who did not report such a history (21.6% vs 7.3%, P = 
0.007). Women with prior history of genital fungal infection were at the greatest risk 
with 27.6% of these patients developing treatment-emergent genital fungal 
infections. No other variables were found to be associated with the occurrence of 
genital fungal infections, either analysed among the entire cohort or by the sexes 
separately. In a simple two-variable logistic regression, the likelihood for developing 
genital fungal infections for female sex and previous genital fungal infections were, 
adjusted odds ratio and 95% confidence interval, OR 4.22 [95%CI 2.48,7.19], P < 
0.001 and OR 2.41 [95%CI 1.04,5.57], P = 0.039, respectively. 
 
Discussion 
Our study, utilising “real-life” clinical data, identified patient sex and prior history of 
genital fungal infection to be the only risk factors for developing genital fungal 
infections with dapagliflozin treatment. Only a small proportion of patients 
discontinued dapagliflozin due to such infections.  
Results from our study are similar to clinical trial data of SGLT2 inhibitors. In a 
pooled analysis of clinical trials utilising dapagliflozin 10mg, the incidence of genital 
fungal infection was 9.7% among women and 4.2% in men. The incidence of genital 
fungal infection among patients with a history of genital infections was 25.0% [9]. In a 
pooled analysis of trials utilising canagliflozin 100mg and 300mg, the incidence of 
genital fungal infections were 10.4% and 11.4% in women and 4.2% and 3.7% in 
men, respectively. Women with a previous history of vulvovaginitis had a higher 
incidence of treatment emergent genital fungal infection (29.0%) in the same 
analysis. Treatment discontinuation due to genital fungal infection occurred in 0.9% 
and 0.5% of the canagliflozin 100mg and 300mg groups, respectively [10]. In a large 
cardiovascular outcome study of empagliflozin, pooled events for the 10mg and 
25mg dose showed the incidence of genital fungal infection to be 10.0% in women 
and 5.0% in men [3]. 
We did not identify other risk factors for developing genital fungal infection with 
dapagliflozin treatment to help with treatment decisions in the clinical setting. 
Baseline HbA1c was not a risk factor, a similar finding noted by Johnsson et al [9] 
and Nyirjesy et al [10]. In contrast, Nyirjesy et al has reported more frequent genital 
fungal infection among women with younger age or higher BMI (but not among men) 
[10]. A low incidence of vulvovaginal infections (<5%) was observed in a study of 
canagliflozin treatment among Japanese patients with type 2 diabetes [11] but we 
did not find a lower incidence of infections in our Asian cohort. A low incidence of 
genital fungal infections was also observed in type 2 diabetes patients with moderate 
renal impairment treated with canagliflozin [12], possibly due to attenuated effects of 
urinary glucose excretion in patients with reduced renal function. We did not find an 
effect of renal function on developing genital fungal infection in our study. However, 
only 5.3% of patients with calculated eGFR in our study had eGFR below 60 
ml/min/1.73m2. Dapagliflozin is not licensed for patients with eGFR below 60 
ml/min/1.73m2 [13]. 
Our study suggests that women with a history of genital fungal infections should be 
counselled closely with regards to the risks of genital infection with dapagliflozin 
treatment. Nonetheless, the risks of treatment should be weighed against the 
beneficial metabolic profile associated with treatment. When starting SGLT2 inhibitor 
treatment, patients may need to be told to look out for the specific symptoms of 
genital fungal infections. A management plan if genital infections occur should also 
be considered, be it to self-treat with topical or oral antifungal therapy, or to seek 
medical review. Recurrent genital infections should prompt consideration of an 
alternative diabetes treatment. 
The strength of our study includes having a large number of participating centres 
with different ethnic groups studied and having pre-specified queries on genital 
fungal infection and urinary symptoms before and after treatment. The limitations 
include the possibility of under-reporting of events due to patient drop-outs or poor 
recall of events. The number of patients with previous urinary tract infections or 
urinary incontinence was also very small so we may not have detected a significant 
interaction with the occurrence of genital fungal infection.  
 
Conclusion 
Women and patients with previous genital fungal infections are at higher risk of 
developing genital fungal infections with dapagliflozin treatment. A history of genital 
fungal infection should be routinely obtained when considering SGLT2 inhibitor 
treatment, and women should be given closer consideration both in terms of the 
decision to start treatment and for monitoring of adverse events.  
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Table 1 - Baseline characteristics (continuous variables) and their association with genital 
fungal infections among patients treated with dapagliflozin 
 n ≥1 Genital fungal infection P value 
  Yes No   
Age 
(years) 
1049 56  11 57  10 0.47 
Duration of diabetes 
(years) 
1048 11  6 12  7 0.27 
HbA1c 
(%; mmol/mol) 
1045 
9.2  1.5; 
77  16 
9.4  1.5; 
79  16 
0.18 
Body mass index 
(kg/m2) 
1023 34.0  7.4 35.4  6.9 0.53 
eGFR* 
(ml/min/1.73m2) 
932 92  18 90  18 0.32 
Variables are shown as mean ± SD  
eGFR; estimated glomerular filtration rate, calculated by the CKD-EPI equation. 
Table 2 - Baseline characteristics (categorical variables) and their association with genital 
fungal infections among 1049 patients treated with dapagliflozin 
 ≥1 Genital fungal infection P value 
 Yes No  
Sex 
     Female 
     Male 
 
63 (13.2) 
19 (3.3) 
 
413 (86.8) 
554 (96.7) 
<0.001 
Ethnicity (n=947) 
     Caucasian 
     Asian 
     Afro-Carribean 
     Mixed 
 
51 (7.1) 
20 (10.8) 
3 (10.7) 
1 (9.1) 
 
671 (92.9) 
166 (89.2) 
25 (89.3) 
10 (90.9) 
 
- 
0.11 (vs Caucasian) 
0.49 (vs Caucasian) 
- 
Previous genital fungal 
infection <1 year 
     Yes 
     No 
 
 
8 (21.6) 
74 (7.3) 
 
 
29 (78.4) 
938 (92.7) 
 
0.007 
Previous urinary tract 
infection <1 year 
     Yes 
     No 
 
 
2 (9.5) 
80 (7.8) 
 
 
19 (90.5) 
948 (92.2) 
0.68 
History of urinary 
incontinence 
     Yes 
     No 
 
 
2 (15.4) 
80 (7.7) 
 
 
11 (84.6) 
956 (92.3) 
0.27 
History of nocturia 
     Yes 
     No 
 
11 (13.6) 
71 (7.3) 
 
70 (86.4) 
897(92.7) 
0.06 
Variables are shown as n (%) 
